Palavra-chave: CHRONIC MYELOID LEUKEMIA

MOLECULAR RESPONSE LASOR AUTOGRAFTING PH CHROMOSSOME NEW DRUGS STEM CELL TRANSPLANTATION PHASE 2 BCR-ABL BRAZILIAN MEDICAL ASSOCIATION DHPLC T315I NILOTINIB EXPANDING NILOTINIB ACESS IN CLINICAL TRIALS DASATINIB ENESTND CYTARABINE INTERFERON-ALPHA DENATURING HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY EBMT DISCONTINUATION PROGRESSION-FREE SURVIVAL OCULAR TREATMENT-FREE REMISSION EUTOS SCORE CML SUBOPTIMAL RESPONSES IRS-1 IMATINIB MESILATE P190, P120, P230 AUTOGRAFTING OF PERIPHERAL-BLOOD RT-PCR T315L NON-MYELOABLATIVE K562 CELLS B3A2 COVID19 TYROSINE KINASE INHIBITORS EXON 6 CHRONIC PHASE TRANSPORTER GENES EBMT RISK SCORES IMATINIB START MUTATION MITOXANTRONE MOLECULAR IMATINIB RESISTANCE POLYMORPHISMS PERIPHERAL BLOOD STEM CELL TRANSPLANTS EXPRESSION PF P190 BONE MARROW TRANSPLANTATION GLEEVEC F359V FEDERAL UNIVERSITY OF MINAS GERAIS GENE EXPRESSION PROFILE CYTOGENETIC CLINICAL TRIAL STATE UNIVERSITY OF CAMPINAS ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION TK INHIBITORS FISH IMATINIB-RESISTANT BCR-ABL1 SECOND-GENERATION DASATINIB-TREATED HMGCLL1 TYROSINE KINASE IMATINIB-RESISTANT OR-INTOLERANT D-HPLC JAK2 V617F